Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    weill AND intravenous (iv) therapy | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486;   Drug: Duravalumab
2 Recruiting Prospective, Double Blind, Placebo Control, Bariatric IV Ace
Condition: Obesity
Interventions: Drug: intravenous acetaminophen;   Drug: Placebo
3 Recruiting Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery
Condition: Video-assisted Thoracic Surgery
Interventions: Drug: IV Acetaminophen;   Drug: Saline Placebo
4 Recruiting BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
Conditions: Metastatic Cancer;   Cancer;   Solid Tumor
Interventions: Drug: BP31510 monotherapy;   Drug: BP31510 in combination with chemotherapy
5 Recruiting Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Conditions: Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma
Intervention: Drug: SIACI of Erbitux and Bevacizumab
6 Recruiting J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Condition: Prostate Cancer
Intervention: Drug: huJ591
7 Recruiting Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Conditions: HER-2 Positive Breast Cancer;   Metastatic Neoplasm
Interventions: Biological: Margetuximab;   Biological: Trastuzumab;   Drug: Capecitabine;   Drug: Eribulin;   Drug: Gemcitabine;   Drug: Vinorelbine
8 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
9 Recruiting The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Condition: Delirium
Interventions: Drug: Ketamine (0.5 mg/kg);   Drug: Normal Saline (placebo);   Drug: Ketamine (1 mg/kg)
10 Recruiting A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Biological: PRM-151
11 Recruiting A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Durvalumab;   Drug: Pomalidomide;   Drug: Dexamethasone
12 Recruiting A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Durvalumab;   Drug: Lenalidomide;   Drug: Dexamethasone
13 Recruiting Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Pain
Intervention: Drug: Radium-223
14 Recruiting 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
15 Recruiting A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: CC-122;   Drug: Ibrutinib;   Drug: Obinutuzumab

Indicates status has not been verified in more than two years